Kelly L Harms1, Lorena Lazo de la Vega2, Daniel H Hovelson2, Samantha Rahrig2, Andi K Cani2, Chia-Jen Liu2, Douglas R Fullen3, Min Wang4, Aleodor A Andea3, Christopher K Bichakjian1, Timothy M Johnson1, Scott A Tomlins5, Paul W Harms6. 1. Department of Dermatology, University of Michigan Medical School, Ann Arbor2Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor. 2. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor4Department of Pathology, University of Michigan Medical School, Ann Arbor. 3. Department of Dermatology, University of Michigan Medical School, Ann Arbor4Department of Pathology, University of Michigan Medical School, Ann Arbor. 4. Department of Pathology, University of Michigan Medical School, Ann Arbor. 5. Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor3Michigan Center for Translational Pathology, University of Michigan, Ann Arbor4Department of Pathology, University of Michigan Medical School, Ann Arbor5Department of Urology, University of Michigan Medical School, Ann Arbor. 6. Department of Dermatology, University of Michigan Medical School, Ann Arbor3Michigan Center for Translational Pathology, University of Michigan, Ann Arbor4Department of Pathology, University of Michigan Medical School, Ann Arbor.
Abstract
Importance: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. In rare cases, the development of an additional cutaneous MCC tumor is clinically consistent with a second primary MCC tumor rather than a cutaneous metastasis, which has important treatment and prognostic implications. Objective: To evaluate genetic relatedness in 4 cases with the clinical diagnosis of multiple primary MCCs. Design, Setting, and Participants: In this case series, 7 cases of clinically designated multiple primary MCC were identified; 4 cases met inclusion criteria for next-generation sequencing (NGS) analysis. Mutations, copy number alterations, and Merkel cell polyomavirus (MCPyV) sequence were analyzed and compared between clinically designated multiple primary tumors to characterize genetic relatedness and hence assess clonality. Patients with clinically designated multiple primary MCC were identified from the multidisciplinary MCC Program at the University of Michigan, a tertiary care center. Main Outcomes and Measures: Four cases of clinically designated multiple primary MCC were characterized by tumor sequencing and targeted MCPyV sequencing to distinguish independent primary tumors from related metastases. Results: Overall, 4 patients in their 70s or 80s were included and analyzed. Cases 1 and 4 were verified as genetically distinct primary tumors and did not harbor similar copy number alterations or demonstrate significant mutational overlap. Cases 2 and 3 were designated as clonally related based on overlapping copy number alterations. In clonally related tumors, chromosomal copy number changes were more reliable than mutations for demonstrating clonality. Regardless of clonality, we found that MCPyV status was concordant for all tumor pairs and MCPyV positive tumors harbored predominatly subclonal mutations. Conclusions and Relevance: Our findings suggest that patients with MCC may develop a second genetically distinct primary tumor; in this case, the subsequent tumor is likely to develop through similar mechanisms of pathogenesis, either MCPyV-mediated or ultraviolet light-mediated. Next-generation sequencing analysis of chromosomal copy number changes and mutations is useful in distinguishing multiple primary MCCs from progression of MCC clinically resembling multiple primaries, allowing appropriate staging of the patient.
Importance: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. In rare cases, the development of an additional cutaneous MCC tumor is clinically consistent with a second primary MCC tumor rather than a cutaneous metastasis, which has important treatment and prognostic implications. Objective: To evaluate genetic relatedness in 4 cases with the clinical diagnosis of multiple primary MCCs. Design, Setting, and Participants: In this case series, 7 cases of clinically designated multiple primary MCC were identified; 4 cases met inclusion criteria for next-generation sequencing (NGS) analysis. Mutations, copy number alterations, and Merkel cell polyomavirus (MCPyV) sequence were analyzed and compared between clinically designated multiple primary tumors to characterize genetic relatedness and hence assess clonality. Patients with clinically designated multiple primary MCC were identified from the multidisciplinary MCC Program at the University of Michigan, a tertiary care center. Main Outcomes and Measures: Four cases of clinically designated multiple primary MCC were characterized by tumor sequencing and targeted MCPyV sequencing to distinguish independent primary tumors from related metastases. Results: Overall, 4 patients in their 70s or 80s were included and analyzed. Cases 1 and 4 were verified as genetically distinct primary tumors and did not harbor similar copy number alterations or demonstrate significant mutational overlap. Cases 2 and 3 were designated as clonally related based on overlapping copy number alterations. In clonally related tumors, chromosomal copy number changes were more reliable than mutations for demonstrating clonality. Regardless of clonality, we found that MCPyV status was concordant for all tumor pairs and MCPyV positive tumors harbored predominatly subclonal mutations. Conclusions and Relevance: Our findings suggest that patients with MCC may develop a second genetically distinct primary tumor; in this case, the subsequent tumor is likely to develop through similar mechanisms of pathogenesis, either MCPyV-mediated or ultraviolet light-mediated. Next-generation sequencing analysis of chromosomal copy number changes and mutations is useful in distinguishing multiple primary MCCs from progression of MCC clinically resembling multiple primaries, allowing appropriate staging of the patient.
Authors: Szilárd Nemes; Anna Danielsson; Toshima Z Parris; Junmei Miao Jonasson; Erik Bülow; Per Karlsson; Gunnar Steineck; Khalil Helou Journal: Genes Chromosomes Cancer Date: 2013-09-02 Impact factor: 5.006
Authors: Christopher K Bichakjian; Lori Lowe; Christopher D Lao; Howard M Sandler; Carol R Bradford; Timothy M Johnson; Sandra L Wong Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: Catherine Grasso; Timothy Butler; Katherine Rhodes; Michael Quist; Tanaya L Neff; Stephen Moore; Scott A Tomlins; Erica Reinig; Carol Beadling; Mark Andersen; Christopher L Corless Journal: J Mol Diagn Date: 2014-11-07 Impact factor: 5.568
Authors: Franz O Smith; Binglin Yue; Suroosh S Marzban; Brooke L Walls; Michael Carr; Ryan S Jackson; Christopher A Puleo; Tapan Padhya; C Wayne Cruse; Ricardo J Gonzalez; Amod A Sarnaik; Michael J Schell; Ronald C DeConti; Jane L Messina; Vernon K Sondak; Jonathan S Zager Journal: Cancer Date: 2015-06-02 Impact factor: 6.860
Authors: Clayton A Fisher; Paul W Harms; Jonathan B McHugh; Paul C Edwards; Javed Siddiqui; Nallasivam Palanisamy; Christopher K Bichakjian; Erika Benavides; Theodora E Danciu Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2014-09-17
Authors: Judit Nagy; Liliána Z Fehér; István Sonkodi; József Lesznyák; Béla Iványi; László G Puskás Journal: Virchows Arch Date: 2005-02-25 Impact factor: 4.064
Authors: Jayasri G Iyer; Barry E Storer; Kelly G Paulson; Bianca Lemos; Jerri Linn Phillips; Christopher K Bichakjian; Nathalie Zeitouni; Jeffrey E Gershenwald; Vernon Sondak; Clark C Otley; Siegrid S Yu; Timothy M Johnson; Nanette J Liegeois; David Byrd; Arthur Sober; Paul Nghiem Journal: J Am Acad Dermatol Date: 2014-02-09 Impact factor: 11.527
Authors: Jürgen C Becker; Andreas Stang; Axel Zur Hausen; Nicole Fischer; James A DeCaprio; Richard W Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K Bichakjian; Selma Ugurel; David Schrama Journal: Cancer Immunol Immunother Date: 2017-11-30 Impact factor: 6.968
Authors: Ryan C DeCoste; Noreen M Walsh; Daniel Gaston; Thai Yen Ly; Sylvia Pasternak; Sam Cutler; Mat Nightingale; Michael D Carter Journal: Mod Pathol Date: 2022-09-08 Impact factor: 8.209
Authors: May P Chan; Komal R Plouffe; Chia-Jen Liu; Nallasivam Palanisamy; Shannon Carskadon; Lili Zhao; Rosalynn M Nazarian; Alison B Durham; Timothy M Johnson; Aleodor A Andea; Rajiv M Patel; Lori Lowe; Douglas R Fullen; Noah A Brown; Scott A Tomlins; Aaron M Udager; Paul W Harms Journal: Mod Pathol Date: 2019-12-19 Impact factor: 7.842
Authors: Kelly L Harms; Lili Zhao; Bryan Johnson; Xiaoming Wang; Shannon Carskadon; Nallasivam Palanisamy; Daniel R Rhodes; Rahul Mannan; Josh N Vo; Jae Eun Choi; May P Chan; Douglas R Fullen; Rajiv M Patel; Javed Siddiqui; Vincent T Ma; Steven Hrycaj; Scott A McLean; Tasha M Hughes; Christopher K Bichakjian; Scott A Tomlins; Paul W Harms Journal: Clin Cancer Res Date: 2021-02-05 Impact factor: 12.531
Authors: Andi K Cani; Emily M Dolce; Elizabeth P Darga; Kevin Hu; Chia-Jen Liu; Jackie Pierce; Kieran Bradbury; Elaine Kilgour; Kimberly Aung; Gaia Schiavon; Danielle Carroll; T Hedley Carr; Teresa Klinowska; Justin Lindemann; Gayle Marshall; Vicky Rowlands; Elizabeth A Harrington; J Carl Barrett; Nitharsan Sathiyayogan; Christopher Morrow; Valeria Sero; Anne C Armstrong; Richard Baird; Erika Hamilton; Seock-Ah Im; Komal Jhaveri; Manish R Patel; Caroline Dive; Scott A Tomlins; Aaron M Udager; Daniel F Hayes; Costanza Paoletti Journal: Mol Oncol Date: 2021-12-20 Impact factor: 7.449
Authors: Leyre A Falto Aizpurua; Min Wang; Hiram A Ruiz; Jorge L Sánchez; May P Chan; Aleodor A Andea; Paul W Harms Journal: JAAD Case Rep Date: 2018-11-03
Authors: Paul W Harms; Monique E Verhaegen; Kevin Hu; Steven M Hrycaj; May P Chan; Chia-Jen Liu; Marina Grachtchouk; Rajiv M Patel; Aaron M Udager; Andrzej A Dlugosz Journal: Mod Pathol Date: 2021-09-30 Impact factor: 7.842